Literature DB >> 20644149

Rapid disease course in African Americans with multiple sclerosis.

I Kister1, E Chamot, J H Bacon, P M Niewczyk, R A De Guzman, B Apatoff, P Coyle, A D Goodman, M Gottesman, C Granger, B Jubelt, L Krupp, M Lenihan, F Lublin, C Mihai, A Miller, F E Munschauer, A B Perel, B E Teter, B Weinstock-Guttman, R Zivadinov, J Herbert.   

Abstract

OBJECTIVE: To investigate utility of a Multiple Sclerosis Severity Scale (MSSS)-based classification system for comparing African American (AA) and white American (WA) multiple sclerosis (MS) subpopulations in the New York State Multiple Sclerosis Consortium (NYSMSC) database. MSSS is a frequency-rank algorithm relating MS disability to disease duration in a large, untreated reference population. Design/
METHODS: Distributions of patients in 6 MSSS-based severity grades were calculated for AA and WA registrants.
RESULTS: There were 419 AA and 5,809 WA patients in the NYSMSC, who had EDSS recorded during years 1-30 since symptom onset. Median EDSS was not different in AA and WA (3.5 vs 3.0, p = 0.60), whereas median MSSS in AA was higher than in WA (6.0 vs 4.8, p = 0.001). AA patients were overrepresented in the 2 most severe grades (41.5% vs 29.3% for WA) and underrepresented in the 2 lowest grades (23.4% vs 35.4%; p < 0.001). In multivariable analysis (ordered logistic and median regression), MSSS for AA remained significantly higher than in WA after adjusting for age, gender, disease duration, disease type distribution, and treatment with disease-modifying therapies.
CONCLUSIONS: The 6-tiered MSSS grading system is a powerful tool for comparing rate of disease progression in subpopulations of interest. MSSS-based analysis demonstrates that African ancestry is a risk factor for a more rapidly disabling disease course.

Entities:  

Mesh:

Year:  2010        PMID: 20644149     DOI: 10.1212/WNL.0b013e3181e8e72a

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  36 in total

1.  An MRI evaluation of grey matter damage in African Americans with MS.

Authors:  Maria Petracca; Wafaa Zaaraoui; Sirio Cocozza; Roxana Vancea; Jonathan Howard; Monika M Heinig; Lazar Fleysher; Niels Oesingmann; Jean-Philippe Ranjeva; Matilde Inglese
Journal:  Mult Scler Relat Disord       Date:  2018-07-12       Impact factor: 4.339

2.  Brain and retinal atrophy in African-Americans versus Caucasian-Americans with multiple sclerosis: a longitudinal study.

Authors:  Natalia Gonzalez Caldito; Shiv Saidha; Elias S Sotirchos; Blake E Dewey; Norah J Cowley; Jeffrey Glaister; Kathryn C Fitzgerald; Omar Al-Louzi; James Nguyen; Alissa Rothman; Esther Ogbuokiri; Nicholas Fioravante; Sydney Feldman; Ohemaa Kwakyi; Hunter Risher; Dorlan Kimbrough; Teresa C Frohman; Elliot Frohman; Laura Balcer; Ciprian Crainiceanu; Peter C M Van Zijl; Ellen M Mowry; Daniel S Reich; Jiwon Oh; Dzung L Pham; Jerry Prince; Peter A Calabresi
Journal:  Brain       Date:  2018-11-01       Impact factor: 13.501

3.  Vitamin D in African Americans with multiple sclerosis.

Authors:  J M Gelfand; B A C Cree; J McElroy; J Oksenberg; R Green; E M Mowry; J W Miller; S L Hauser; A J Green
Journal:  Neurology       Date:  2011-05-24       Impact factor: 9.910

4.  Interleukin-17- and interleukin-22-secreting myelin-specific CD4(+) T cells resistant to corticoids are related with active brain lesions in multiple sclerosis patients.

Authors:  Ana Cristina Wing; Joana Hygino; Thais B Ferreira; Taissa M Kasahara; Priscila O Barros; Priscila M Sacramento; Regis M Andrade; Solange Camargo; Fernanda Rueda; Soniza V Alves-Leon; Claudia Cristina Vasconcelos; Regina Alvarenga; Cleonice A M Bento
Journal:  Immunology       Date:  2015-12-02       Impact factor: 7.397

5.  Multiple sclerosis in US minority populations: Clinical practice insights.

Authors:  Omar Khan; Mitzi J Williams; Lilyana Amezcua; Adil Javed; Kristin E Larsen; Jennifer M Smrtka
Journal:  Neurol Clin Pract       Date:  2015-04

6.  Retinal damage and vision loss in African American multiple sclerosis patients.

Authors:  Dorlan J Kimbrough; Elias S Sotirchos; James A Wilson; Omar Al-Louzi; Amy Conger; Darrel Conger; Teresa C Frohman; Shiv Saidha; Ari J Green; Elliot M Frohman; Laura J Balcer; Peter A Calabresi
Journal:  Ann Neurol       Date:  2015-01-13       Impact factor: 10.422

Review 7.  Clinical Characteristics of Multiple Sclerosis in African-Americans.

Authors:  Veronica P Cipriani; Sara Klein
Journal:  Curr Neurol Neurosci Rep       Date:  2019-11-13       Impact factor: 5.081

8.  Immunopathological patterns from EAE and Theiler's virus infection: Is multiple sclerosis a homogenous 1-stage or heterogenous 2-stage disease?

Authors:  Nicholas E Martinez; Fumitaka Sato; Seiichi Omura; Alireza Minagar; J Steven Alexander; Ikuo Tsunoda
Journal:  Pathophysiology       Date:  2012-05-26

9.  Efficacy and tolerability of dimethyl fumarate in White-, African- and Hispanic- Americans with multiple sclerosis.

Authors:  Lana Zhovtis Ryerson; Rivka Green; Gladyne Confident; Krupa Pandey; Benjamin Richter; Tamar Bacon; Carrie Sammarco; Lisa Laing; Jennifer Kalina; Ilya Kister
Journal:  Ther Adv Neurol Disord       Date:  2016-08-04       Impact factor: 6.570

10.  Disability in multiple sclerosis: a reference for patients and clinicians.

Authors:  Ilya Kister; Eric Chamot; Amber R Salter; Gary R Cutter; Tamar E Bacon; Joseph Herbert
Journal:  Neurology       Date:  2013-02-20       Impact factor: 9.910

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.